AVEO shares jump on Astellas pact

ValBrickates Kennedy

BOSTON (MarketWatch) -- Shares of AVEO Pharmaceuticals
AVEO, +2.57%
jumped 9% in early trading Thursday on news that it and Japanese drug maker Astellas Pharma [jp:4503] are partnering to commercialize AVEO's oncology drug tivozanib for all markets outside of Asia. Tivozanib is currently in Phase III testing for the treatment of kidney cancer. Under the deal, AVEO will receive $125 million up front, plus up to $1.3 billion in potential milestone payments along with certain royalties. Kyowa Hakko Kirin still retains the rights to commercialize the product in Asia.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.